CDKN2B and cancer: Regarding CDK4/6 inhibitors, somatic mutations in CDK 4 inhibitor B (CDKN2B) were associated with an increased risk of cancer-associated VTE, suggesting a potential pathophysiological link between CDK4/6-inhibiton and thrombotic risk.62